Patients with advanced sporadic MTC should be offered molecular testing since somatic RET mutations have been shown to lead to more aggressive disease, including higher T- and N-stage, and increase the rate of distant metastasis (84, 108). The gene discussed is RET; the disease is medullary thyroid gland carcinoma.